Related Experiment Video

Updated: Jun 12, 2025

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.1K

Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling

Ioan-Alexandru Minciună1,2, Raluca Tomoaia1,2, Dragos Mihăilă1

  • 15th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

Current Issues in Molecular Biology
|September 27, 2024
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) show potential in managing atrial remodeling, a key factor in atrial fibrillation (AF) and heart failure (HF). This review explores their mechanisms and clinical implications for cardiovascular disease prevention.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Atrial cardiomyopathy and remodeling are central to atrial fibrillation (AF) and heart failure (HF) progression.
  • These processes involve complex structural and functional changes, driven by mechanical stress and electrical disturbances.
  • Sodium-glucose cotransporter 2 inhibitors (SGLT2is), established for type 2 diabetes, offer significant cardiovascular benefits, particularly in HF management.

Purpose of the Study:

  • To review the molecular mechanisms by which SGLT2is impact atrial remodeling.
  • To clarify the potential benefits and limitations of SGLT2is in the context of atrial remodeling.
  • To provide insights for integrating SGLT2is into strategies for preventing AF and HF progression.

Main Methods:

  • Literature review of randomized clinical trials and preclinical studies.
  • Analysis of molecular pathways affected by SGLT2is in cardiac tissue.
  • Synthesis of current evidence on SGLT2i effects on atrial structure and function.

Main Results:

  • Emerging data suggest SGLT2is may positively influence atrial remodeling.
  • Specific molecular targets and pathways modulated by SGLT2is are being identified.
  • The overall effectiveness and optimal use of SGLT2is for atrial remodeling require further investigation.

Conclusions:

  • SGLT2is hold promise for mitigating atrial remodeling, potentially impacting AF and HF.
  • Understanding the molecular mechanisms is crucial for optimizing SGLT2i therapy in cardiovascular disease.
  • Further research is needed to confirm the role of SGLT2is in preventing atrial remodeling and related cardiovascular events.

Keywords:
SGLT2 inhibitorsatrial cardiomyopathyatrial fibrillationatrial remodelingheart failure

More Related Videos

Electrophysiological Assessment of Murine Atria with High-Resolution Optical Mapping08:19

Electrophysiological Assessment of Murine Atria with High-Resolution Optical Mapping

Published on: February 22, 2018

9.8K
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.7K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.9K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.4K